RCS - RUA Life Sciences - Full Year Results Investor Presentation

Rua Life SciencesAnnouncement

13/07/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210713:nRSM9901Ea&default-theme=true

RNS Number : 9901E  RUA Life Sciences PLC  13 July 2021

RNS REACH

 

13 July 2021

 

RUA Life Sciences plc

("RUA" or the "Company")

 

Full Year Results Investor Presentation

Results Webinar: open to all investors

RUA Life Sciences (AIM:RUA), the holding company of a group of medical device
businesses focused on the exploitation of the world's leading long-term
implantable biostable polymer (Elast-Eon(TM)), will be conducting an Investor
Presentation webinar covering their FY results for the year ended 31 March
2021.

The event will take place at 2.00pm on Friday 16th July 2021.

The online presentation is open to all existing and potential shareholders.
Questions can be submitted during the presentation to be addressed at the end.

To register for the event, please go
to: https://www.equitydevelopment.co.uk/news-and-events/rua-life-sciences-full-year-results-investor-presentation-16th-july-2021
(https://protect-eu.mimecast.com/s/0IwACZwVMHQR6XhznsJh?domain=equitydevelopment.co.uk)

A recording will be available after the event
at https://www.equitydevelopment.co.uk/research/tag/rua-life-sciences
(https://protect-eu.mimecast.com/s/vh61C1YrZSqm4LsGfWMb?domain=equitydevelopment.co.uk)
 

 For further information contact:

RUA Life Sciences

Bill Brown,
Chairman
      Tel: +44 (0) 77 3071 8296

David Richmond, CEO
                    Tel: +44 (0) 78 9999 6400

 

Equity
Development
Tel: +44 (0) 20 7065 2692

Hannah Crowe

 

Shore Capital (Nominated Adviser and Joint
Broker)

Tom Griffiths/David Coaten
Tel: +44 (0) 20 7408 4080

 

Cenkos Securities plc (Joint Broker)               Tel: +44 (0) 20
7397 8900

Russell Cook/Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

 

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life
Sciences Plc (formerly known as AorTech International Plc) acquired RUA
Medical Devices Limited to create a fully formed medical device business. RUA
Life Sciences is the holding company of the Group's four trading businesses,
each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and
enabling medical devices with Elast-Eon™, a long-term implantable
polyurethane.

Whether it is licensing Elast-Eon™, manufacturing a device or component or
developing next generation medical devices, a RUA Life Sciences business is
pursuing our vision.

 

Elast-Eon™'s biostability is comparable to silicone while exhibiting
excellent mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic extrusion and
moulding techniques. With over 7 million implants and over 14 years of
successful clinical use, RUA's polymers are proven in long-term life enabling
applications.

 

The Group's four business units are:

 RUA Medical:           End-to-end contract designer and manufacturer of medical devices and
                        implantable fabric specialist.
 RUA Biomaterials:      Licensor of Elast-Eon™ polymers to the medical device industry.
 RUA Vascular:          Commercialisation of large bore polymer sealed grafts and soft tissue patches.
 RUA Structural Heart:  Development of polymeric leaflet systems for heart valves.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRGDRIGBDGBD